Colorectal Cancer Therapeutics strategies and Product Pipeline Review 2017

Pune, India, 13th October 2017: WiseGuyReports announced addition of new report, titled “Colorectal Cancer Drug Development Pipeline Review, 2017”.

Pune, India - October 13, 2017 /MarketersMedia/ —

Summary
This report provides an overview of the colorectal cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for anal, rectal and colorectal cancer, and features dormant and discontinued projects.

Anal cancer starts in the anus. Symptoms include rectal bleeding, rectal itching, a lump or mass at the anal opening, pain or a feeling of fullness in the anal area, narrowing of stool, pain or a feeling of fullness in the anal area

GET SAMPLE REPORT @ https://www.wiseguyreports.com/sample-request/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Rectal cancer affects the lower part of the colon, which connects the large bowel to the anus. The common signs and symptoms of rectal cancer include a change in bowel habits, diarrhea, constipation, or feeling that the bowel does not empty completely, blood, either bright red or very dark in the stool, stools that are narrower than usual, general abdominal discomfort such as frequent gas pains, bloating, fullness or cramps, weight loss with no known reason, constant tiredness and vomiting.

Finally, colorectal cancer is a cancer that starts in the colon or the rectum. Colorectal cancers begin as a growth called a polyp on the inner lining of the colon or rectum. Symptoms include abdominal pain and tenderness in the lower abdomen, blood in the stool, diarrhea, constipation, change in bowel habits, narrow stools and weight loss with no known reason.

The size of these pipelines ranges from 10 products in rectal cancer to 581 products in colorectal cancer. Across all three of these indications, however, kinases, immune-related proteins, DNA-related proteins and viral proteins are common targets, closely reflecting the current treatment landscape of these diseases.

Scope
- Which companies are the most active within the pipeline for colorectal cancer therapeutics?
- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?
- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?
- What are the most important R&D milestones and data publications to have happened in the field of colorectal cancer?

Reasons to buy
- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication
- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each
- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of these
- Understand the composition of the pipeline in terms of molecule type, molecular target, mechanism of action and route of administration

Table of Content: Key Points
1 Table of Contents 4
1.1 List of Tables 5
1.2 List of Figures 10
2 Introduction 11
2.1 Colorectal Cancer Report Coverage 11
2.2 Anal Cancer - Overview 11
2.3 Rectal Cancer - Overview 11
2.4 Colorectal Cancer - Overview 11
3 Therapeutics Development 12
3.1 Anal Cancer 12
3.2 Rectal Cancer 16
3.3 Colorectal Cancer 18
4 Therapeutics Assessment 56
4.1 Anal Cancer 56
4.2 Rectal Cancer 63
4.3 Colorectal Cancer 71
5 Companies Involved in Therapeutics Development 100
5.1 Anal Cancer 100
5.2 Rectal Cancer 108
5.3 Colorectal Cancer 114
6 Dormant Projects 241
6.1 Anal Cancer 241
6.2 Rectal Cancer 241
6.3 Colorectal Cancer 242
7 Discontinued Products 261
7.1 Anal Cancer 261
7.2 Colorectal Cancer 261
8 Product Development Milestones 265
8.1 Anal Cancer 265
8.2 Rectal Cancer 278
8.3 Colorectal Cancer 280
…Continued

ACCESS REPORT @ https://www.wiseguyreports.com/reports/2385276-colorectal-cancer-drug-development-pipeline-review-2017

Get in touch:
LinkedIn: www.linkedin.com/company/4828928
Twitter: https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: WISEGUY RESEARCH CONSULTANTS PVT LTD
Address: Office No. 528, Amanora Chambers
Phone: +91 841 198 5042

Source URL: https://marketersmedia.com/colorectal-cancer-therapeutics-strategies-and-product-pipeline-review-2017/250073

For more information, please visit http://www.wiseguyreports.com

Source: MarketersMedia

Release ID: 250073

More News From dailyworldfeed.com

Dish, Amazon chiefs discuss wireless partnership: WSJ

Oct 23, 2017

(Reuters) - Dish Network Corp Chief Executive Charlie Ergen and Amazon.com Inc head Jeff Bezos have discussed a partnership to enter the wireless business, the Wall Street Journal reported, citing people familiar with the matter.Amazon could help bankroll a network Dish is building focused on the "Internet of Things", and could possibly offer its Prime members an option to pay a little more per month for a connectivity or phone plan, the Journal reported on Thursday, citing one person. Amazon could also offer a one-way broadcast signal for its Prime video on Dish's airwaves, the paper said, citing a person...

China's LeEco founder resigns as chair of listed unit after public plea for patience

Oct 23, 2017

By Sijia JiangHONG KONG (Reuters) - The founder of China's debt-laden LeEco resigned as chairman of its main listed unit on Thursday, just hours after making a public plea for patience amid a deepening financial crisis at the entertainment, electronics and electric vehicles group.Leshi Internet Information & Technology Corp Beijing said Jia Yueting will remain controlling shareholder without any role, having resigned as chief executive in May to focus on the electric car business, of which he will now become chairman.The announcement came after Jia on social media promised to repay debt and reaffirmed LeEco's electric car commitment. "Please give...

Symantec to buy Israeli cybersecurity firm Fireglass

Oct 23, 2017

By Liana B. BakerSAN FRANCISCO (Reuters) - Symantec Corp is acquiring Israeli cybersecurity startup Fireglass, the company said on Thursday, in a small deal designed to boost its products that protect corporate email and web browsing from threats.Symantec is paying an undisclosed sum for the Tel Aviv-based company of about 40 employees. Fireglass specializes in an area of security called "browser isolation," a technology that creates virtual websites allowing users to browse any content without having viruses touch their network."Browser isolation" is an area that Symantec had been looking to enter for some time, Chief Executive Greg Clark said in...

LeEco's Jia resigns as Leshi chairman, takes up car unit post

Oct 23, 2017

HONG KONG (Reuters) - LeEco founder Jia Yueting has resigned as chairman of its main listed unit, Leshi Internet Information & Technology Corp, and will take up the chairman role at LeEco's car unit, the company said.Jia no longer holds any post at Leshi, the Shenzhen-listed company said in a filing after market close on Thursday. Jia remains its controlling shareholder, it said. Jia will take up the role of chairman of LeEco's car business, LeEco announced via the official WeChat account of its electric car brand LeSEE. Jia's role changes come after he issued a public statement where he...

Tencent unit seeks to withhold shareholding information, raising governance concerns

Oct 23, 2017

By Elzio BarretoHONG KONG (Reuters) - Tencent Holdings' online publishing subsidiary has sought a waiver from Hong Kong listing rules to allow it to withhold shareholding information of some executives, drawing criticism from corporate governance advocates.China Literature Ltd requested the unusual exemption from the Hong Kong bourse, saying revealing the three executives' stakes "would attract unnecessary attention amongst Tencent's employees and would likely create an unfavorable and political working environment which would significantly distort Tencent's workplace culture and distract them from their business duties within [Tencent] as well as their duties as directors of ourCompany." The online publisher filed for...

About Me

Get yourself immersed in engaging topics right here. Daily World Feed is a multi-platform media, providing you latest breaking news straight from the industry.

Contact us: sales@dailyworldfeed.com